Rasuvo is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with severe, active rheumatoid arthritis (RA). Rasuvo may be prescribed in cases where first-line therapy such as non-steroidal anti-inflammatory drugs (NSAIDS) are not effective or tolerated. Rasuvo is also referred to by its drug name, Methotrexate.
Rasuvo is an immunomodulator, or in other words, a drug that modulates the immune system. Rasuvo is also referred to as a disease-modifying antirheumatic drug (DMARD) or a slow-acting antirheumatic drug (SAARD). It is an antimetabolite that blocks the synthesis of purine, a protein the body needs in order to produce lymphocytes. Lymphocytes are a type of white blood cell active in the immune system. Rasuvo is believed to work by interfering with lymphocytes and preventing them from attacking the joints.
How do I take it?
Prescribing information states that Rasuvo is administered once a week by subcutaneous injection.
Rasuvo comes in the form of a single-dose auto-injector.
The FDA-approved label for Rasuvo lists common side effects including dizziness, headache, hair loss, mouth sores, rash, blood cell changes, nausea, stomach upset, abdominal pain, and increased sensitivity to sunlight.
Rare but serious side effects listed for Rasuvo include toxic effects on organ systems, fetal harm, and impairment of the reproductive system.
For more details about this treatment, visit:
Rasuvo – Medac Pharma